Hemotherapy Decisions Flashcards
blood products considered to be cellular components
whole blood, red blood cells, granulocytes
blood products considered to be plasma components
platelet products, cryoprecipitate, fresh frozen plasma, other plasma components
blood products considered to be hematopoietic progenitor cell products
bone marrow, peripheral blood stem cells, cord blood preparations
goals of transfusion
increase tissue oxygenation and/or restore hemostasis
what product is used to treat inadequate oxygen carrying capacity?
red cells
what product is used to treat insufficient coagulation proteins?
FFP, cryo
what product is used to treat inadequate hemostasis?
[;ate;ets
expected response per dose of red cell transfusion
1 g/dl
expected response per dose of FFP
25% increase in factor products
expected response per dose of platelets
30-50,000 1 hour post transfusion
expected response per dose of cryo
fibrinogen increase 50 mg/dl
expected response per dose of granulocytes
usually no demonstrable increase in neutrophil count
common transfusion trigger for red cells
Hgb <7 g/dl
common transfusion triggers for FFP
aPTT and/or PTT increase >1.5 times upper normal limit
common transfusion trigger for platelets
plt count <10,000
common transfusion trigger for cryo
fibrinogen <100 mg/dl
common transfusion trigger for granulocytes
documented sepsis unresponsive to antimicrobial therapy
common adult dose for RBC
1 unit
common adult dose for FFP
10-20 mg/kg body weight (often 2 units)
common adult dose for platelets
1 apheresis or 4-6 pooled whole blood derived units
common adult dose for cryo
10 units of 1 unit/kg body weight
common adult dose for granulocytes
1 unit
first lab tests used to assess need to transfusion
CBC, PTT, PT, INR, fibrinogen
INR value that indicates need for ooagulation factor replacement
> 2.0
best treatment of hypovolemia without anemia
crystalloid or colloid solutions
crystalloid solutions
normal saline, lactated Ringers
what is first line of correction to replenish intravascular volume?
crystalloids
disadvantage of crystalloids
move outside vascular space rapidly and volume is not sustained
colloids
hydroxyethyl starch, dextran, 5% albumin
advantage of colloids
maintaining intravascular volume
symptoms of anemia
low Hgb weakness headache dyspnea angina
symptoms of hypovolemia
cold extremities hypotension acidosis reduced arterial/central venous pressure decreased urine output mental status changes
types of anemia: causes
blood loss
increased RBC destruction
decreased RBC production
extrinsic causes of hemolytic anemia
alloantibody-mediated WAIHA cold agglutinin syndrome PCH PNH drug-related mechanical microangiopathic anemia
intrinsic causes of hemolytic anemia
hemoglobin disorders
membrane defects
enzyme defects
causes of microcytic anemia
iron deficiency thalassemia lead poisoning anemia of chronic disease sideroblastic anemia
causes of normocytic anemia
myelophthisic anemia
renal/low EPO
anemia of chronic disease
marrow hypo/dys/aplasia
causes of macrocytic anemia
megaloblastic
nonmegaloblastic
megaloblastic anemia causes
decreased B12, decreased folate, medication
nonmegaloblastic anemia causes
marrow hypo/dys/aplasia, alcoholism, liver disease, hypothyroid
anemia caused by shortage of iron in body
iron deficiency anemkia
common causes of iron deficiency anemia
heavy menstrual bleeding ulcer cancer polyp prolonged use of aspirin or NSAIDS
anemia caused by diet lacking in B12 or other key nutrients
vitamin deficiency anemia
diseases associated with anemia of chronic disease
cancer HIV/AIDS rheumatoid arthritis Crohn's chronic inflammatory diseases
rare life-threatening anemia caused by decrease in bone marrow’s ability to product red blood cells
aplastic anemia
causes of aplastic anemia
infections
drugs
autoimmune diseases
anemia caused by affect of disease on production of bone marrow, from mild alteration in blood production to complete life-threatening shutdown of blood-making process
anemia associated with bone marrow disease
anemia that develops when red cells are destroyed faster than bone marrow can replace them
hemolytic anemia
anemia caused by defective form of hemoglobin that forces red blood ells to assume an abnormal crescent shape
sickle cell anemia
what causes anemia in sickle cell?
irregular-shaped red cells die prematurely, resulting in chronic shortage of blood cells
indications for red cell transfusion
symptomatic anemia
increased need for oxygen carrying capacity
contraindications for red cell transfusions
pharmacologically treatable anemia
coagulation deficiencies
only volume expansion needed
indications for RBC exchange transfusion
sickle cell
severe parasitic infection
severe methemoglobinemia
severe hyperbilirubinemia of newborn
whole blood storage when collected for whole blood
CPDA 35 days
whole blood collection to be converted into components
CPD or CP2D 21 days (without additive)
final HCT of packed red cells in CPD, CP2D
65-80%
red cell shelf life with additive solution
42 days
final HCT of red cells with additive solution
55-65%
function of adenine in additive soluion
provides substrate for ATP synthesis
what additive solutions contain mannitol?
AS-1 (Adsol), AS-5 (Optisol)
FDA requirement for completion of red cell transfusion
4 hours
advantages of leukoreduced RBCs
decreased risk of febrile non-hemolytic trx rxn
decreased risk of CMV transmission
decreased risk of HLA alloimmunization
average unit of whole blood contains how many WBCs?
2x10^9 leukocytes
average unit of packed red cells contains how many WBCs?
2x10^8 leukocytes
leukocyte reduced packed red cells contain what number of WBCs?
<5x10^6 leukocytes
quality control requirements of leukocyte reduced RBCS
reduce WBC count to <5x10^6 in at least 95% of units sampled
>85% RBC recovery
purpose of irradiation
prevents proliferation of transfused T lymphocytes
3 conditions for GVHD to occur
transfusion or transplantation of immunocompetent T lymphs
histocompatibility differences between graft and recipient
immunocompromised patient (usually)
shelf life of irradiation red cells
28 days, not to exceed original expiration
advantages of frozen/deglycerolized RBCs
long term storage of rare antigen types
IgA deficient product
reduced risk of allergic and febrile reactions
expiration of deglycerolized RBCs
24 hours
RBCs processed for freezing must be placed in freezer within what time frame after removal from refrigeration?
4 hours
red cells in CPD or CPDA must be frozen within ___ from collection
6 days
red cells in additive solution may be frozen when?
anytime before expiration
red cells in any preservative can be rejuvenated and frozen when?
anytime between 3 days after collection and 3 days after expiration
deglycerolization must retain what percent of original red cell volume?
80%
average unit of deglycerolized red cells contains how many WBCs?
1x10^7 leukocytes
oxygen dissociation is based on?
affinities of tissues for oxygen and ability of red cells to release oxygen
RBC storage changes over time
decrease ATP
decrease 2,3-DPG
increased plasma potassium
function of 2,3-DPG
controls movement of oxygen from red blood cells to body tissues
more 2,3-DPG in cells = ___ oxygen delivered to tissues
more
less 2,3-DPG in cells = ___ oxygen delivered to tissues
less
what does oxygen dissociation curve show?
percent saturation of hemoglobin at various partial pressures of oxygen
factors that influence oxygen binding
temperature
2,3-DPG level
what happens to hemoglobin at high partial pressures of oxygen?
binds to oxygen to form oxyhemoglobin –> travel to tissues deprived of oxygen and producing CO2 –> partial pressure of oxygen decreases –> oxyhemoglobin releases oxygen to tissues
influence of increased temperature on oxygen binding
SHIFT RIGHT. increases amount of oxygen and hemoglobin, decreases concentration of oxyhemoglobin, tissues receive more oxygen
influence of decreased 2,3-DPG on oxygen binding
SHIFT LEFT. hgb has increased affinity for oxygen and less release to tissues
shift right
more oxygen to tissues
shift left
less oxygen to tissues
result of multiple transfusions of 2,3-DPG depleted stored blood
shifts O2 curve to left, less oxygen released in tissues and organs, reduced oxygen carrying capacity
purpose of rejuvenation solutions
biochemically modify RBCs to improve oxygen transport function
2,3-DPG levels after rejuvenation
1.5x normal
when can red cells be rejuvenated?
after expiration date
how long can rejuvenated red cells be stored?
2-4 hours as saline-red blood cell suspension
glycerolized and frozen up to 10 years
prophylactic inpatient transfusion threshold for platelets
10,000
platelet transfusion threshold for patients already bleeding or to undergo surgery
50,000
platelet transfusion threshold for intracerebral, pulmonary, or ophthalmic hemorrhage
100,000
determination of response rate to platelet transfusion calculated by?
Corrected Count Increment or platelet recovery percentage
immune mediated destruction of platelets is evidenced by platelet count obtained when?
10 minutes to 1 hour post-transfusion
what accounts for more immune mediated platelet refractoriness?
class I HLA (A and B loci)
what patient population is most likely to be platelet refractory?
oncology patients receiving myeloablative chemotherapy
immune-mediated platelet refractoriness causes
HLA antibodies
ABO antibodies
platelet specific antibodies
non-immune mediated platelet refractoriness causes
DIC
sepsis
neutropenic fever
splenomegaly
non-immune mediated causes of platelet refractoriness are typically associate with?
initial increase in platelet count followed by inadequate 24-hour post-transfusion platelet counts
DIC is associated with what in regards to platelet refractoriness?
platelet consumption
sepsis and neutropenic fever are associated with what in regards to platelet refractoriness?
platelet activation and utilization
splenomegaly is associated with what in regard to platelet refractoriness?
platelet sequestration
contraindications for platelet transfusion
ITP TTP platelet dysfunction caused by extrinsic factors hemolytic uremic syndrome heparin-induced thrombocytopenia
acquired thrombocytopenia due to immune platelet destruction not caused by an acquired condition
ITP (primary immune thrombocytopenia)
thrombocytopenia in which patient and donor platelets are rapidly cleared by circulating antibody
ITP
treatment for children with ITP
usually have spontaneous remission; platelet transfusion not necessary
treatment goal in adult with ITP
reduce risk of bleeding, not to normalize platelet count
treatment of ITP in adults
glucocorticoids and IVIG, including anti-RH(D) (WinRho) to Rh positive patients
rare blood coagulation disorder causing extensive microscopic clots to form in small blood vessels throughout the body
TTP (Thrombotic thrombocytopenic purpura)
are platelets indicated for patients with TTP?
no - can cause increase in platelet aggregates
treatment options for TTP
plasmapheresis to remove organ-damaging aggregates
platelet count in platelet concentrate
> 5.5x10^10 platelets in 40-70 ml plasma
platelet count in apheresis platelet
> 3x10^11 platelets
1 apheresis platelet = ___ platelet concentrates
4-6
platelet transfusion ABO requirements
no requirement, donor plasma ABO-compatible to recipients red cells when transfusing infants or large volumes to adults
Rh negative to Rh negative when possible, especially women of childbearing age
indications for plasma transfusion
massive transfusion
warfarin anticoagulation reversal
multiple coagulopathy due to liver disease/damage
therapeutic plasma exchance
contraindications for plasma transfusion
volume replacement
otherwise correctable coagulopathy
normalizing abnormal PT and/or PTT in absence of bleeding
single factor deficiencies when concentrate source is available
plasma product with decreased levels of fibrinogen, factor VIII, vWF, fibronectin, and factor XIII
plasma cryoprecipitate reduced
plasma cryoprecipitate reduced is useful in treatment of what?
TTP, hemolytic uremic syndrome
cold-insoluble portion of plasma that precipitates when thawed at 1-6C
cryoprecipitate AHF
cryoprecipitate volume per unit
10-15 mL
factors found in cryo
fibrinogen factor VIII:C factor VIII:vWF factor XIII fibronectin
only concentrate source of factor I
cryoprecipitate
standard adult dose of cryo
10 units
standard child dose of cryo
5 units based on 1 unit/7-10 kg body weight
standard child dose of cryo
5 units based on 1 unit/7-10 kg body weight
minimum IU of factor VIII:C in each unit of cryo
80
minimum fibrinogen in each unit cryo
150 mg
indications for cryo
hypofibrinogenemia/dysfibrinogenemia bleeding associated with fibrinogen deficiencies intracranial hemorrhage vWD unresponsive to DDAVP uremic bleeding unresponsive to DDAVP factor XIII deficiency fibrin sealant (topical use)
contraindications for cryo
hemophilia A
vWD when factor concentrates are available
hazards of cryo transfusion
transfusion-transmitted infectious diseases
allergic reactions to plasma proteins
indications for adult granulocyte transfusion
transient marrow depression
bacterial or fungal infections unresponsive to antimicrobial therapy for more than 48 hours
congenital neutrophil dysfunction (CGD)
indications for neonatal and pediatric granulocyte transfusion
neutropenia <3000/ul
bacterial or fungal septicemia not responsive to antimicrobial therapy
what is given to increase harvest of granulocytes?
oral dexamethasone
subcutaneous G-CSF
granulocyte storage
room temp, 24 hours
contraindications for granulocyte transfusion
viral or parasitic infection
hormone-like substances naturally made by the body that cause bone marrow to make more blood cells
hematopoietic growth factors
hematopoietic growth factor that stimulates proliferation, maturation, and differentiation of erythroid precursors
erythropoietin
alternatives to blood transfusions
volume expanders (colloids and crystalloids)
growth factors (EPO)
intraoperative or post-operative blood salvage
blood substitutes
plasma derivatives
plasma derivatives derived from?
source plasma
recovered plasma
plasma collected specifically for the purpose of manufacturing plasma derivatives
source plasma (plasma donor centers)
plasma separated from whole blood donations
recovered plasma
how are plasma derivatives prepared?
fractionation of plasma
plasma derivative used to treat hypovolemic shock and burn patients
5% albumin
plasma derivative used to treat cerebral edema
25% albumin
normal serum albumin %
5%
salt poor albumin percent
25%
high-titer IVIG used to treat ITP for Rh positive patients
WinRho
plasma derivative examples
albumin RhIg IVIG WinRho antithrombin activated protein C alpha-1-antitrypsin lyophilized clotting factors
preparation of plasma derived lyophilized factors
treated with solvent and detergent which inactivates lipid-enveloped viruses (HIV, HBV, HPC)
preparation of recombinant lyophilized factors
genetically engineered
what is the risk of viral disease transmission from recombinant lyophilized factors?
none
2 types of plasma derived factor IX
complex of factors II, VII, IX, and X
monoclonal factor IX
lyophilized factor VIII plasma derived preparation
cryoprecipitate purified so that only factor VIII remains
pharmacologic alternatives to blood products
desmopressin (DDAVP)
recombinant growth factors
fibrinolytic inhibitors
purpose of desmopressin (DDAVP)
promotes hemostasis
used to mild factor VIII deficiencies
recombinant growth factors examples
EPO
G-CSF
examples of fibrinolytic inhibitors
epsilon-aminocaproic acid (EACA)
tranexamic acid
aproptinin
widely used hemostatic drug; synthetic analog of natural hormone vasopressin
DDAVP
hormone that controls red cell production
EPO
stimulates bone marrow to produce granulocytes and stem cells and release them into the blood stream
G-CSF
synthetic inhibitor of plasmin-plasminogen system
EACA
only potent anti-fibrinolytic agent commercially available in US
EACA